Solving solubility challenges with EUDRAGIT ® functional polymers

Overview

Almost half of currently marketed drug products, and around 90 percent of those in clinical development are associated with poor drug solubility or permeability. Over the past two decades, Evonik has worked with customers to choose the right polymer excipient, process technology and formulation solutions to overcome poor solubility of APIs.

In this webinar, Evonik’s experts Thomas Endres and Priyanka Haksar explain how EUDRAGIT^® functional polymers can be used to improve drug solubility and permeability. They also discuss how the portfolio can enhance drug solubility in parallel with achieving other functionality outcomes.

As a participant of this webinar your will learn about:

Selecting the right carrier for solubility enhancement of poorly soluble drugs
The use of EUDRAGIT^® polymers in manufacturing processes like spray drying, hot melt extrusion and top-spray granulation
EUDRAGIT^® polymers as carriers for amorphous solid solutions

Experts featuring this session

Dr. Thomas Endres
Manager New Products & Materials
Evonik Health Care
Vita

Thomas Endres is an expert in polymeric excipients for oral and parenteral dosage forms and has extensive experience in the management of innovation and customer projects.

Thomas joined Evonik in 2012 and has held roles as project manager in the R&D department in Germany, and as biomaterials manager in the U.S.

He studied macromolecular chemistry before completing his doctoral research in polymer chemistry at the Institute of Pharmaceutical Technology at the University of Marburg in Germany.

Priyanka Haksar
Head of of Formulation Development Orals
Vita

Priyanka Haksar is Head of Formulation Development Orals at Evonik Health Care. She has extensive experience in the development of drug delivery technologies to improve drug safety and performance and is author and co-author of several patent applications and scientific publications.

Priyanka holds a master’s degree in pharmacy from SNDT University Mumbai. Before joining Evonik in 2007, she worked for several R&D departments of Indian pharmaceutical companies, focusing on the development of generic ophthalmic and solid oral formulations.